A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma

Cancer Prevention Research

Volumn 5, Issue 6, 2012, Pages 855-863

  Edwards, Todd L ^a,b   Shrubsole, Martha J ^a,c   Cai, Qiuyin ^a,c   Li, Guoliang ^a   Dai, Qi ^a   Rex, Douglas K ^e   Ulbright, Thomas M ^e   Fu, Zhenming ^a   Murff, Harvey J ^a,c   Smalley, Walter ^a,d   Ness, Reid ^d   Zheng, Wei ^a,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CAUCASIAN; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; FEMALE; GENE REPLICATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM;

ADENOMA; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLONIC POLYPS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENOTYPING TECHNIQUES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84866443359     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0459     Document Type: Article

References (52)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Fearon ER, Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
3. Vakiani E, Yantiss RK. Pathologic features and biologic importance of colorectal serrated polyps. Adv Anat Pathol 2009;16:79-91.
4. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7-13. (Pubitemid 32634915)
5. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40. (Pubitemid 27157312)
6. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21. (Pubitemid 33741877)
7. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001;7:1048-51. (Pubitemid 32937386)
8. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-55. (Pubitemid 46179475)
9. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10:7727-37. (Pubitemid 39557538)
10. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95. (Pubitemid 44315981)
11. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
12. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82. (Pubitemid 44958508)
13. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenomarecurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36. (Pubitemid 36929412)
14. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
15. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. (Pubitemid 36297996)
16. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-66.
17. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:365-75. (Pubitemid 351650597)
18. Gao F, Liao C, Liu L, Tan A, Cao Y, Mo Z. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Colorectal Dis 2009;11:893-901.
19. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:376-89. (Pubitemid 351650598)
20. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 2003;14:403-11. (Pubitemid 36999974)
21. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002;11:1305-15.
22. Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 2005;14:1613-8. (Pubitemid 40995069)
23. Sansbury LB, Bergen AW, Wanke KL, Yu B, Caporaso NE, Chatterjee N, et al. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:494-501.
24. Buchowski MS, Schlundt DG, Hargreaves MK, Hankin JH, Signorello LB, Blot WJ. Development of a culturally sensitive food frequency questionnaire for use in the Southern Community Cohort Study. Cell Mol Biol (Noisy-le-grand) 2003;49:1295-304.
25. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009;5:e1000529.
26. The International HapMap Consortium. HapMap Homepage. [cited May 7 2012]. Available from: http://hapmap.ncbi.nlm.nih.gov/. 2012.
27. The 1000 Genomes Project Consortium. 1000 Genomes Project. [cited May 7 2012]. Available from: http://www.1000genomes.org/. 2012.
28. BRLMM-P: a Genotype Calling Method for the SNP 5.0 Array. Affymetrix, Inc. [cited May 7 2012]. Available from: http://media.affymetrix.com/support/ technical/whitepapers/brlmmp-whitepaper.pdf. 2012.
29. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75. (Pubitemid 47330214)
30. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9. (Pubitemid 44141658)
31. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007;39:906-13. (Pubitemid 47014502)
32. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190-1.
33. Poole EM, Hsu L, Xiao L, Kulmacz RJ, Carlson CS, Rabinovitch PS, et al. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2010;19:547-57.
34. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009;18:2726-33.
35. Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, Dixon DA, et al. Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis 2009;24:647-54.
36. Peters WH, te Morsche RH, Roelofs HM, Mathus-Vliegen EM, Berkhout M, Nagengast FM. COX-2 polymorphisms in patients with familial adenomatous polyposis. Oncol Res 2009;17:347-51.
37. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005;26:449-57. (Pubitemid 40246567)
38. Ueda N, Maehara Y, Tajima O, Tabata S, Wakabayashi K, Kono S. Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study. Cancer Sci 2008;99:576-81. (Pubitemid 351228576)
39. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14:616-9. (Pubitemid 40489204)
40. Pichaud F, Delage-Mourroux R, Pidoux E, Jullienne A, Rousseau-Merck MF. Chromosomal localization of the type-I 15-PGDH gene to 4q34-q35. Hum Genet 1997;99:279-81. (Pubitemid 27073337)
41. Frank B, Hoeft B, Hoffmeister M, Linseisen J, Breitling LP, Chang-Claude J, et al. Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk. Carcinogenesis 2011;32:190-6.
42. Hoeft B, Linseisen J, Beckmann L, Muller-Decker K, Canzian F, Husing A, et al. Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis 2010;31:466-72.
43. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-23. (Pubitemid 40223783)
44. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468-73. (Pubitemid 39657428)
45. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009;106:9409-13.
46. Baba Y, Nosho K, Shima K, Goessling W, Chan AT, NgK, et al.PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2010;19:822-31.
47. Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol 2010;176:1469-83.
48. Ogawa Y, Suzuki T, Oikawa A, Hosono K, Kubo H, Amano H, et al. Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009;382:720-5.
49. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 2010;116:2806-14.
50. Loffler I, Grun M, Bohmer FD, Rubio I. Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2. BMC Cancer 2008;8:380.
51. Fujino H, Toyomura K, Chen XB, Regan JW, Murayama T. Prostaglandin E regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol 2011;81:379-87.
52. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet 2012;131:217-34.